24-h urinary sodium excretion and the risk of adverse outcomes
- PMID: 32602794
- PMCID: PMC7877963
- DOI: 10.1080/07853890.2020.1780469
24-h urinary sodium excretion and the risk of adverse outcomes
Abstract
Aims: The objective was to evaluate whether sodium intake, assessed with the gold standard 24-h urinary collections, was related to long-term incidence of death, cardiovascular disease (CVD) and diabetes mellitus (DM).
Methods: A cohort of 4630 individuals aged 25-64 years collected 24-h urine samples in 1979-2002 and were followed up to 14 years for the incidence of any CVD, coronary heart disease (CHD), stroke, heart failure (HF) and DM event, and death. Cox proportional hazards models were used to estimate the association between the baseline salt intake and incident events and adjusted for baseline age, body mass index, serum cholesterol, prevalent DM, and stratified by sex and cohort baseline year.
Results: During the follow-up, we observed 423 deaths, 424 CVD events (288 CHD events, 142 strokes, 139 HF events) and 161 DM events. Compared with the highest quartile of salt intake, persons in the lowest quartile had a lower incidence of CVD (hazard ratio [HR] 0.70; 95% confidence interval [CI], 0.51-0.95, p = .02), CHD (HR 0.63 [95% CI 0.42-0.94], p = .02) and DM (HR 0.52 [95% CI 0.31-0.87], p = .01). The results were non-significant for mortality, HF, and stroke.
Conclusion: High sodium intake is associated with an increased incidence of CVD and DM.
Keywords: Cardiovascular disease; coronary heart disease; diabetes; heart failure; sodium; stroke.
Conflict of interest statement
Dr. Vuori reports grants from Aarne Koskelo Foundation, Juho Vainio Foundation, and The state research funding of Finland used on this work and doctoral thesis in general. Drs. Harald, Jousilahti, Valsta, Jula, and Laatikainen have nothing to disclose. Dr. Tuomilehto reports grants from Bayer AG, grants from Boehringer Ingelheim, personal fees from Eli Lilly, personal fees and non-financial support from Merck, personal fees from MSD, personal fees from Novo Nordisk, grants from Sanofi, during the conduct of the study; other from Orion pharma, outside the submitted work. Dr. Salomaa reports personal fees and other from Novo Nordisk, personal fees from Sanofi, grants from Bayer AG, outside the submitted work. Dr. Niiranen reports grants from Academy of Finland, grants from Emil Aaltonen Foundation, grants from Finnish Medical Foundation, grants from Paavo Nurmi Foundation, outside the submitted work.
Figures
References
-
- Malta D, Petersen KS, Johnson C, et al. . High sodium intake increases blood pressure and risk of kidney disease. From the science of salt: a regularly updated systematic review of salt and health outcomes (August 2016 to March 2017). J Clin Hypertens (Greenwich)). 2018;20(12):1654–1665. - PMC - PubMed
-
- O'Donnell MJ, Yusuf S, Mente A, et al. . Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA. 2011;306(20):2229–2238. - PubMed
-
- Joosten MM, Gansevoort RT, Mukamal KJ, et al. ; PREVEND Study Group . Sodium excretion and risk of developing coronary heart disease. Circulation. 2014;129(10):1121–1128. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous